Gait Characteristics and Cognitive Evolution in Parkinson Disease

NCT ID: NCT04297800

Last Updated: 2025-01-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-11-09

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Parkinson's disease (PD) is a chronic progressive nervous system disease with gradual motor impairment. Cognitive dysfunction is common in PD, even in the early stages, and it is characterized by impairments in executive, attention, memory, language and visuospatial function. Motor symptoms, in particular, alterations in gait, have been studied in clinical practice to assess disease progression, and its response to treatments, both farmacological and physiotherapeutic.

Recent research on wearable technology in PD has shown that motor tests can be automated using wearable technology to eliminate human supervision and patient-reported data. Particularly, the quantitative gait analysis by using inertial devices has been proposed as a sensitive tool to longitudinally monitor gait worsening, response to dopaminergic treatment over time and cognitive dysfunction in PD patients.

The aim of this prospective multicente observational study is to investigate whether the dysfunction of specific gait parameters may be correlated to cognitive impairment (Attention/Executive Function Domain) in a cohort of ambulatory PD patients followed for 3 years.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective multicenter observational study with annual follow-up assessments over 3 years.

Gait is assessed by an inertial device (BTS G-WALK). G- WALK is an easy-to-use solution to obtain accurate, objective and quantitative spatial-temporal gait data. The device is a wireless system consisting of an inertial sensor composed by a triaxial accelerometer, a magnetic sensor, and a triaxial gyroscope that positioned on lumbar/ or sacral segments allows a functional gait analysis.

Cognitive performance is evaluated with a neuropsychological battery designed to assess memory, executive /attention, and visuospatial domains.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Both sex
* Aged between 55-74 years
* Diagnosis of idiopathic PD based on MDS clinical diagnostic criteria
* Hoehn \& Yahr (H\&Y) stages 2 to 3 at enrollment, independently by PD duration
* Clinical-pharmacological stabilization until 3 months before the enrollment
* DBS treatment (stable stimulation parameters until 6 months before the enrollment)

Exclusion Criteria

* Evidence of neurodegenerative and secondary parkinsonism
* Dementia ( (score \<25 on the Mini Mental State Examination - MMSE)
* Psychiatric disorder (Beck Depression Inventory-II - BDI-II Score \>19)
* Presence of organ failure (Modified Cumulative Illness Rating Scale - CIRS \> 2)
* Orthopedic disorder or co-morbidities that may affect gait
* Drug and alcohol use
Minimum Eligible Age

55 Years

Maximum Eligible Age

74 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dario Alimonti, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

ASST- Papa Giovanni XXIII

Francesco Biroli, MD

Role: STUDY_CHAIR

Fondazione per la Ricerca Ospedale di Bergamo (FROM)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

ASST- Papa Giovanni XXIII

Bergamo, , Italy

Site Status

Spedali Civili di Brescia

Brescia, , Italy

Site Status

Ospedale San Gerardo di Monza

Monza, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GECO-PARKINSON STUDY

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.